Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs
, , , , , y
20 ago 2020
Acerca de este artículo
Publicado en línea: 20 ago 2020
Páginas: 45 - 55
Recibido: 29 abr 2020
Aceptado: 28 may 2020
DOI: https://doi.org/10.2478/acm-2020-0006
Palabras clave
© 2020 K Prso et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Prso, K
Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in BratislavaMartin, Slovakia
Zidekova, N
Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in BratislavaMartin, Slovakia
Dohal, M
Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in BratislavaMartin, Slovakia
Porvaznik, I
Department of Clinical Microbiology, National Institute for Tuberculosis, Lung Diseases and Thoracic SurgeryVyšné Hágy, Slovakia
Faculty of Health, Catholic UniversityRužomberok, Slovakia
Prso, M
Clinic of Children and Adolescents, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, and Martin University HospitalMartin
Kertys, M
Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in BratislavaMartin, Slovakia
Mokry, J
Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in BratislavaMartin, Slovakia